In Vitro Maturation of Human Eggs

Launched by COLORADO CENTER FOR REPRODUCTIVE MEDICINE · Oct 7, 2024

Keywords

ClinConnect Summary

CCRM Fertility is conducting a study to explore a new method called in vitro maturation (IVM) for helping women with infertility, especially those diagnosed with polycystic ovary syndrome (PCOS). IVM uses fewer hormones than traditional in vitro fertilization (IVF), making it a potentially more affordable option with fewer side effects. Women who qualify for this study will receive a complimentary cycle of IVM treatment, which includes a consultation, fertility tests, and some medications.

To be eligible, participants should be infertile women with a good ovarian reserve, specifically those with an antral follicle count greater than 24 and an AMH level above 3.5 ng/ml. Additionally, they need to have a body mass index (BMI) under 35 and agree to have embryos tested for genetic conditions. Participants should also plan to transfer embryos within four months after the IVM cycle. If you’re interested, this study offers a chance to receive cutting-edge fertility treatment at no cost while helping advance research in this important area.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Infertile women diagnosed with PCOS or polycystic ovaries, or infertile women with good ovarian reserve
• • Antral follicle count (AFC) greater than 24
• • AMH greater than 3.5 ng/ml
• • Body Mass Index less than 35
• • Accept to have embryos biopsied for PGT
• • Intend to perform embryo transfer within 4 months after completing the IVM cycle
• • Paternal (or donor) age \<45, ejaculated sperm collection only (partner frozen and donor sperm acceptable), sperm morphology (strict criteria) \>1%, motility \> 20% and sperm count \> 10 million per ml (so samples can be prepared through standard procedure)
• Exclusion Criteria:
• • More than 2 failed IVF cycles